Edited by: Werner Aberer
C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study
Version of Record online: 2 SEP 2011
© 2011 John Wiley & Sons A/S
Volume 66, Issue 12, pages 1604–1611, December 2011
How to Cite
Craig, T. J., Bewtra, A. K., Bahna, S. L., Hurewitz, D., Schneider, L. C., Levy, R. J., Moy, J. N., Offenberger, J., Jacobson, K. W., Yang, W. H., Eidelman, F., Janss, G., Packer, F. R., Rojavin, M. A., Machnig, T., Keinecke, H.-O. and Wasserman, R. L. (2011), C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study. Allergy, 66: 1604–1611. doi: 10.1111/j.1398-9995.2011.02702.x
- Issue online: 27 OCT 2011
- Version of Record online: 2 SEP 2011
- Accepted for publication 5 August 2011
- C1 esterase inhibitor concentrate;
- C1-inhibitor replacement therapy;
- Hereditary Angioedema
To cite this article: Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke H-O, Wasserman RL. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604–1611.
Background: The placebo-controlled study International Multicentre Prospective Angioedema C1-INH Trial 1 (I.M.P.A.C.T.1) demonstrated that 20 U/kg C1 esterase inhibitor (C1-INH) concentrate (Berinert®; CSL Behring, Marburg, Germany) is effective in treating acute abdominal and facial Hereditary Angioedema (HAE) attacks.
Methods: I.M.P.A.C.T.2 was an open-label extension study of I.M.P.A.C.T.1 to evaluate the safety and efficacy of long-term treatment with 20 U/kg C1-INH for successive HAE attacks at any body location. Efficacy outcomes included patient-reported time to onset of symptom relief (primary) and time to complete resolution of all symptoms (secondary), analysed on a per-patient and per-attack basis. Safety assessments included adverse events, vital signs, viral safety and anti-C1-INH antibodies.
Results: During a median study duration of 24 months, 1085 attacks were treated in 57 patients (10–53 years of age). In the per-patient analysis, the median time to onset of symptom relief was 0.46 h and was similar for all types of attacks (0.39–0.48 h); the median time to complete resolution of symptoms was 15.5 h (shortest for laryngeal attacks: 5.8 h; 12.8–26.6 h for abdominal, peripheral and facial attacks). Demographic factors, type of HAE, intensity of attacks, time to treatment, use of androgens and presence of anti-C1-INH antibodies had no clinically relevant effect on the efficacy outcomes. There were no treatment-related safety concerns. No inhibitory anti-C1-INH antibodies were detected in any patient.
Conclusions: A single dose of 20 U/kg C1-INH concentrate is safe and provides reliable efficacy in the long-term treatment of successive HAE attacks at any body location.
See Special Feature Page for this article here